Mometasonfuroaat Basic Pharma (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometasonfuroaat Basic Pharma, is a glucocorticoid presented as a nasal spray for nasal use. It provides anti‑inflammatory relief for allergic rhinitis, including seasonal and perennial forms, in patients who need corticosteroid therapy.

GNH USA supplies Mometasonfuroaat Basic Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards and is manufactured under strict GMP conditions. Its consistent batch‑to‑batch potency supports reliable clinical outcomes.

Mometasone furoate nasal spray is a glucocorticoid that reduces inflammation in the nasal passages for allergic conditions.

- Allergic rhinitis: reduces nasal congestion, itching, sneezing and rhinorrhea, improving airflow. - Seasonal allergic rhinitis: controls symptoms triggered by pollen exposure, providing relief during allergy seasons. - Perennial allergic rhinitis: offers year‑round symptom control for indoor allergen‑induced nasal inflammation.

Mometasone furoate nasal spray may cause local and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nasal irritation or burning. - Epistaxis (nosebleeds). - Headache. - Sore throat.

Serious or Rare Side Effects: - Nasal septal perforation. - Cataracts or increased intra‑ocular pressure. - Adrenal suppression with prolonged high‑dose use.

When using Mometasone furoate nasal spray, consider the following precautions.

- Hypersensitivity: discontinue if patient experiences rash, swelling or breathing difficulty. - Recent nasal surgery or trauma: avoid use until healed. - Duration of therapy: limit continuous use to the recommended period, usually not exceeding three months without medical review. - Concomitant use with other nasal corticosteroids: avoid to reduce systemic exposure. - Systemic effects: monitor for signs of adrenal insufficiency during long‑term high‑dose therapy. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Mometasone furoate nasal spray can interact with other medicines; awareness of these interactions helps maintain safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure. - Concurrent use of other intranasal corticosteroids: additive glucocorticoid effects.

Moderate Interactions (Monitor Closely): - Systemic glucocorticoids: may enhance overall corticosteroid activity. - Immunosuppressants (e.g., cyclosporine): monitor for increased infection risk. - Antiviral agents metabolized by CYP3A4 (e.g., ritonavir): observe for altered drug levels.